药捷安康-B:替恩戈替尼片新药上市申请获国家药品监督管理局受理

Core Viewpoint - The announcement indicates that the new drug application for Tienogratinib tablets has been accepted by the National Medical Products Administration of China, aimed at treating adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have previously received at least one systemic therapy and FGFR inhibitor treatment [1] Group 1 - The drug Tienogratinib is intended for patients with advanced cholangiocarcinoma [1] - The application has been prioritized and included in the breakthrough therapy list [1]